Update
January 2008

No. 2008-07

To: Blood Banks, Dentists, Dispensing Physicians, Federally Qualified Health Centers, Inpatient Hospital Providers, Nurse Practitioners, Nursing Homes, Outpatient Hospital Providers, Pharmacies, Physician Assistants, Physician Clinics, Physicians, Podiatrists, Rural Health Clinics, HMOs and Other Managed Care Programs

Pharmacy Consolidation for Wisconsin Medicaid and BadgerCare Plus Managed Care Members

Currently, HMOs and special managed care programs are responsible for managing health services, including pharmacy services, for their members. As a result of the Department of Health and Family Services pharmacy consolidation, effective for dates of service on and after February 1, 2008, pharmacy services and some drugrelated supplies for managed care members will be reimbursed by fee-for-service.

Background

As part of the state budget, the legislature directed the Department of Health and Family Services (DHFS) to save money on pharmacy services for members enrolled in Wisconsin Medicaid and BadgerCare Plus. To meet this directive, changes will be made to pharmacy services for members enrolled in Wisconsin Medicaid HMOs (now known as BadgerCare Plus HMOs), SSI HMOs, and most special managed care programs.

Currently, HMOs and special managed care programs are responsible for managing health services, including pharmacy services, for their members. As a result of the DHFS pharmacy consolidation, effective for dates of service (DOS) on and after February 1, 2008, pharmacy services and some drug-related supplies for managed care members will be reimbursed by fee-for-service.

The following are exceptions to this policy change:

 Prescription drugs and related services for members enrolled in the Program of All-Inclusive Care for the

- Elderly (PACE) and the Family Care Partnership (formerly the Wisconsin Partnership Program) will continue to be provided by the special managed care program.
- Physician-administered drugs will also continue to be managed by the member's HMO or special managed care program.

Transition Period

From February 1, 2008, to April 1, 2008, a continuity of care transition period will be provided in an effort to ensure no interruption in service for members. Providers are encouraged to begin working with members enrolled in BadgerCare Plus in order to minimize any problems that may occur after April 1, 2008.

During the transition period, drug prior authorization (PA) and diagnosis restrictions will *not* apply to prescriptions for managed care members transitioning to fee-for-service.

BadgerCare Plus has advised members to talk with their physicians and pharmacy providers about drugs they are taking. During the transition period, prescribers may receive an increase in call volume from members and pharmacy providers to change a prescription to a drug covered by BadgerCare Plus or to complete the appropriate PA request form and submit it to the pharmacy provider.

Pharmacy providers may need to increase the frequency of contact with prescribers to change members' prescriptions to drugs covered by BadgerCare Plus or to request the appropriate completed PA request form. Requests may also include providing noncovered services or over-the-counter (OTC) drugs.

Members are required to receive prescriptions from a Wisconsin Medicaid-certified pharmacy. Members who receive prescriptions from specialty or mail-order pharmacies that are not Wisconsin Medicaid certified will not be able to continue to receive services from these pharmacies beginning February 1, 2008. Pharmacy providers may need to contact the specialty or mail-order pharmacy to transfer prescriptions.

Pharmacy Policies That Now Apply

Effective for DOS on and after February 1, 2008, the following fee-for-service polices and procedures will apply for pharmacy services provided to members enrolled in managed care programs:

- Age restrictions.
- Claim submission for Medicare Part D.
- Gender restrictions.
- Member Lock-in.
- Noncovered services.
- Over-the-counter drugs.
- Prospective Drug Utilization Review.
- Pharmaceutical Care.

Note: If age- and gender-restricted drugs are prescribed outside the current BadgerCare Plus policy and the drugs are medically necessary, claims must be submitted on the Noncompound Drug Claim, HCF 13072 (06/03), along with the Pharmacy Special Handling Request form, HCF 13074 (06/06). Providers should include supporting documentation with each claim submission. Providers may refer to all-provider and pharmacy publications for more detailed information about the feefor-service polices.

Prior Authorization

During the transition period (February 1, 2008, to April 1, 2008), PA is *not* required for prescriptions for managed care members transitioning to fee-for-service. However, effective for DOS on and after April 2, 2008, all fee-for-service policies and procedures will apply, including the PA and diagnosis restriction policies.

Preferred Drug List Prior Authorization

If a member is taking a non-preferred drug, the pharmacy provider should contact the prescriber to switch the member's prescription to a preferred drug.

If it is medically necessary for a member to remain on a non-preferred drug, a PA request must be submitted. Prescribers are required to complete the appropriate Prior Authorization/Preferred Drug List (PA/PDL) form and submit it to the pharmacy provider where the prescription will be filled. Pharmacy providers may begin submitting PA requests to fee-for-service (not the HMO or special managed care program) for non-preferred drugs on and after January 3, 2008. Prior authorization is required for non-preferred drugs with DOS on and after April 2, 2008.

Prior authorization requests may be submitted using the Specialized Transmission Approval Technology-Prior Authorization (STAT-PA) system for DOS on and after January 3, 2008. For STAT-PA requests, the DOS may be up to 31 days in the future or up to 14 days in the past.

Refer to Attachment 1 of this *Update* for the current PDL. The Pharmacy page of the Medicaid Web site at *dhfs.wisconsin.gov/medicaid/pharmacy/index.htm* also contains the most current PDL. Providers should refer to the Pharmacy page as the PDL may change monthly.

Members currently taking non-preferred drugs in the PDL classes listed below may remain on the drug indefinitely without PA (i.e., grandfathering). If it is medically necessary for a prescriber to change a member

to another non-preferred drug in a grandfathered class, PA is required.

Grandfathering occurs in the following classes as designated on the PDL:

- Alzheimer's agents.
- Antidepressants, Other.
- Antidepressants, SSRI.
- Anti-Parkinson agents.
- Anticonvulsants.
- Atypical antipsychotics.
- Stimulants and related agents.

Wisconsin BadgerCare Plus providers may access the PDL using their personal digital assistants (PDAs) or personal computers through ePocrates. ePocrates' products provide clinical reference information specifically for health care providers at the point of care. Prescribers and pharmacy providers who use PDAs may also subscribe and download the PDL by accessing the ePocrates Web site at www.epocrates.com/.

Brand Medically Necessary Prior Authorization

Fee-for-service requires PA for brand medically necessary prescription drugs on the Maximum Allowable Cost (MAC) list. Prescribers are required to handwrite "Brand Medically Necessary" on these prescriptions. Brand medically necessary PA requests must be submitted on the paper Prior Authorization/Brand Medically Necessary Attachment (PA/BMNA), HCF 11083 (03/05). Pharmacy providers are required to complete the Prior Authorization Request Form (PA/RF), HCF 11018 (06/03), and submit it with a completed and signed PA/BMNA from the prescriber, along with any supporting documentation, to BadgerCare Plus.

Pharmacy providers are required to indicate the appropriate one-digit National Council for Prescription Drug Programs (NCPDP) Dispense as Written (DAW) code on each claim for a brand medically necessary drug.

Providers should refer to the data tables on the Pharmacy page of the Medicaid Web site at dhfs.wisconsin.gov/medicaid4/pharmacy/data_tables/index.htm for a list of brand medically necessary drugs that require PA.

Explanation of Benefits

From February 1, 2008, to April 1, 2008, pharmacy providers will receive informational Explanation of Benefit (EOB) messages as a reminder about the upcoming policy changes that result from the pharmacy consolidation.

During the transition period, pharmacy providers will receive the following informational EOB messages when submitting claims for members moving to fee-for-service from managed care:

- 434 "Non-preferred drug is being dispensed to an HMO member. Effective 04/02/08, FFS PA is required. Please refer to the PDL."
- 459 "BMN drug is being dispensed to an HMO member. Effective 04/02/08, FFS PA is required.
 Please refer to Medicaid Update 2005-24."

Additional Fee-for-Service Policies

Copayments

Effective for DOS on and after February 1, 2008, with the implementation of BadgerCare Plus, most members will be required to pay a copayment. The following copayments will apply to Wisconsin Medicaid and BadgerCare Plus Standard Plan members:

- \$3.00 for each brand name drug.
- \$1.00 for each generic or compound drug.
- \$0.50 for each OTC drug.

There is a copayment maximum of \$12.00 per member, per month, per pharmacy for legend drugs. There is no monthly maximum on the copayment amount for OTC drugs.

Providers are prohibited from collecting copayments from the following Standard Plan members:

- Nursing home residents.
- Pregnant women.
- Members under 18 years of age who are members of a federally recognized tribe.
- Members under 18 years of age with incomes at or below 100 percent of the Federal Poverty Level.

Federal law permits states to charge members a copayment for certain covered services. Providers are required to request copayments from members; however, they may not deny services to a member who fails to make a copayment.

Chapter 49.45(18), Wis. Stats., requires providers to make a reasonable attempt to collect copayment from the member unless the provider determines that the cost of collecting the copayment exceeds the amount to be collected. Pharmacy providers are required to dispense drugs even if members are unable to pay their copayments; however, providers may bill members for the copayment later.

Providers should verify that they are collecting the correct copayment for services as some services have monthly or annual copayment limits. Providers may not collect member copayments in amounts that exceed Standard Plan copayment limits.

Drug-Related Supplies

As a result of drugs being reimbursed on a fee-for-service basis, some drug-related supplies will also be reimbursed on a fee-for-service basis. Refer to Attachment 2 for a list of reimbursable drug-related supplies. Only drug-related supplies listed in the attachment are reimbursable by fee-for-service. This attachment is also available in the data tables on the Pharmacy page of the Medicaid Web site at dlps.wisconsin.gov/medicaid4/pharmacy/data_tables/index.htm. Providers should refer to the data tables often, as changes may occur frequently.

Claims for drug-related supplies should be submitted with the appropriate Healthcare Common Procedure Coding System procedure code indicated. Copayments for drug-related supplies are required to be applied as appropriate.

Providers may also refer to the Disposable Medical Supply (DMS) Index and publications on the Medicaid Web site at *dhfs.wisconsin.gov/medicaid/* for information about policies and procedures for DMS.

HealthCheck "Other Services"

Certain OTC drugs that are not covered by fee-forservice may be covered by HealthCheck "Other Services" for members under 21 years of age. Refer to the HealthCheck "Other Services" Covered by Wisconsin Medicaid Without Prior Authorization data table on the Pharmacy page of the Medicaid Web site for a list of HealthCheck "Other Services" drugs that do not require PA. Prior authorization is required for all other noncovered OTC drugs.

Providers may refer to the Pharmacy Handbook for more information about HealthCheck "Other Services."

Emergency Medication Dispensing

The emergency medication dispensing policy allows providers to dispense up to a 14-day supply of a drug in situations where the pharmacy provider or prescriber deem it medically necessary. Medications dispensed in emergency situations do not require PA.

This policy overrides drug restriction policies and all PA policies including the PDL, brand medically necessary, and diagnosis restriction policies; however, other polices still apply, such as member eligibility and noncovered services policies still apply.

When subsequent refills are dispensed, all current drug restriction and PA policies still apply. BadgerCare Plus encourages pharmacy providers to dispense an emergency supply of a medication when they determine it is medically necessary or an emergency. An emergency

medication supply may be dispensed if a member receives a prescription for a drug with any type of restriction, including diagnosis restriction, PA requirement, age, or sex restrictions, and the physician cannot be reached to obtain the appropriate documentation to override the restriction.

The February 2007 *Update* (2007-14), titled "Emergency Medication Dispensing," contains more information about claim submission procedures for medications dispensed in an emergency.

For More Information

Providers may send questions about the pharmacy consolidation via e-mail to pharmacyconsolidation@dhfs.state.wi.us.

Providers may also refer to the following for more information about the pharmacy consolidation:

- The Pharmacy Consolidation page on the Medicaid Web site at dhfs.wisconsin.gov/medicaid4/pharmacy/ consolidation/index.htm.
- The SeniorCare Drug Search Tool on the BadgerCare Plus Web site at wisconsinedi.org/SeniorCareDrugInquiry/.
- Provider Services at (800) 947-9627 or (608) 221-9883.

The BadgerCare Plus Update is the first source of program policy and billing information for providers. All information applies to Medicaid and BadgerCare Plus unless otherwise noted in the *Update*.

Wisconsin Medicaid and BadgerCare Plus are administered by the Division of Health Care Access and Accountability, Wisconsin Department of Health and Family Services, P.O. Box 309, Madison, WI 53701-0309.

For questions, call Provider Services at (800) 947-9627 or (608) 221-9883 or visit our Web site at *dhfs.wisconsin.gov/medicaid/*.

PHC 1250

ATTACHMENT 1 Preferred Drug List

(A copy of the Preferred Drug List is located on the following pages.)

				(Revis	ed 01	1/02/08)				
Angiotensin Modulato	rs		Analgesics, Narcotics (co			Antiemetics, Oral (cont.	.)		Antivirals, Influenza (cont.)	
enazepril, HCTZ		Р	Darvon-N	SCN	NP	Cesamet (Oral)		NP	rimantadine	F
aptopril, HCTZ		P	Fentora	001	NP	Kytril		NP	Relenza	F
nalapril, HCTZ		P P	Lynox	SCN	NP	Marinol (Oral)		NP	Tamiflu	F
osinopril, HCTZ		P	Opana Danier DC CC		NP NP	Antifungals, Oral		В	Antivirals, Other	
sinopril, HCTZ loexipril, HCTZ (Univa:	co/Linicotic)	NP	Panlor DC, SS Synalgos-DC		NP NP	clotrimazole		P P	acyclovir famciclovir	F
uinapril, HCTZ (Univa:	sc/Official)	NP	Androgenic Agents		INF	fluconazole griseofulvin		P	Valtrex	F
andolapril (Mavik)		NP	Androderm		Р	itraconazole	DR	Р	Agents for BPH	
ceon		NP	Androgel		Р	ketoconazole	DIC	Р	doxazosin	F
Itace		NP	Testim		NP	nystatin		P	finasteride	F
ekturna		NP	Angiotensin Receptor Blo	ckers		terbinafine	DR	Р	terazosin	F
ngiotensin Modulato	rs/CCB Comb.		Avapro, Avalide		Р	Gris-Peg		Р	Avodart	F
nlodipine/benazepril		Р	Benicar, HCT		Р	Mycostatin		Р	Flomax	F
arka		Р	Cozaar, Hyzaar		Р	Vfend		Р	Uroxatral SCN	F
zor		NP	Diovan, HCT		Р	Ancobon		NP	Cardura XL	N
xforge		NP	Micardis, HCT		Р	Grifulvin V Tablets		NP	Beta Blockers	
exxel		NP	Atacand, HCT		NP	Noxafil		NP	acebutolol	F
cne Agents			Teveten, HCT		NP	Sporanox (liquid)		NP	atenolol	F
enprox		P	Anticoagulants, Injectable	es		Antifungals, Topical			betaxolol	F
enzoyl peroxide		P	Arixtra		P	clotrimazole/betametha	sone	P	bisoprolol	F
indamycin		Р	Fragmin		P	ciclopirox (gel, liquid)		P	carvedilol	F
ythromycin		Р	Lovenox	SCN	P	econazole nitrate		P	labetalol	F
etinoin		P P	Innohep Anticonyulcants		NP	ketoconazole	oinalar -	P P	metoprolol, succinate	F
rne-mycin zelex		P	Anticonvulsants		Р	nystatin, nystatin/triamo		P NP	nadolol pindolol	F
reiex inac BPO		P	carbamazepine clonazepam		P	ciclopirox cream, suspens Ertaczo	OIUI I	NP NP	propranolol, LA	F
etin-A micro, Pump		P	ethosuximide		P	Exelderm		NP	sotalol	
etin-A micro, Pump izorac		P	gabapentin		P	Extina		NP	timolol	
ythromycin, benzoyl p	eroxide	r NP	mephobarbital		P	Loprox (shampoo)	SCN	NP	Cartrol	
ralia	0,1140	NP	oxcarbazepine		Р	Mentax	3014	NP	Coreg CR	
nzaclin Gel	SCN	NP	phenobarbital		Р	Naftin		NP	Innopran XL	
enzamycinpak	SCN	NP	phenytoin		Р	Oxistat		NP	Levatol	
ndagel	SCN	NP	primidone		P	Vusion		NP	Bladder Relaxant Preparations	
ferin	SCN	NP	valproic acid		Р	Xolegel		NP	oxybutynin, ER	
ac CS		NP	zonisamide		Р	Antihistamines, Nonsec	dating		Enablex	- 1
oclin		NP	Carbatrol		Р	Ioratadine tab, syrup,-D		Р	Oxytrol	
va		NP	Celontin		Р	fexofenadine (Allegra, su		NP	Sanctura	F
aron	SCN	NP	Depakote, ER, sprinkle		Р	Clarinex, Clarinex Syrup	SCN	NP	VesiCare	
obenz Micro		NP	Diastat		Р	Semprex-D		NP	Detrol, LA	1
IOX	SCN	NP	Equetro		Р	Zyrtec tab, syrup, -D		NP	Sanctura XR	1
az	SCN	NP	Felbatol		Р	Antimigraine, Triptans			Bone Resorption Suppression	
oclir		NP	Gabitril		Р	Amerge	QL	Р	Fosamax, Plus D	F
ana		NP	Keppra		Р	Axert	QL	P	Miacalcin	F
zheimer's Agents			Lamictal		Р	Imitrex	QL	P	Actonel, with Calcium	1
icept, ODT		Р	Lyrica		Р	Maxalt, MLT	QL	Р	Boniva	1
elon		Р	Mebaral	SCN	Р	Frova	QL	NP	Didronel	1
amenda		Р	Peganone		Р	Relpax	QL	NP	Evista	-
ognex		NP	Topamax		Р	Zomig, Nasal, ZMT	QL	NP	Fortical	1
elon patch		NP	lamotrigine dispertabs		NP	QL - Quantity Limits apply		18	Bronchodilators, Anticholinergio	
zadyne, ER		NP	Phenytek		NP	tablets, 6 sprays, 8 injecti			ipratropium/albuterol	- 1
			Tegretol XR		NP	Antiparkinson's Agents	5		Atrovent, HFA	
algesics, Narcotics	-Long-Acting		Antidepressants, Other			benztropine		P	Combivent	!
ntanyl transdermal		P	budeprion XL 300 mg		P	carbidopa/levodopa		P	Spiriva	ı
ethadone		P	bupropion, SR		P	selegiline		P	Bronchodilators, Beta Agonists	
orphine ER		P P	mirtazapine		P P	trihexyphenidyl		P P	albuterol, sulfate ER	
ycodone ER Idian		P	trazodone venlafaxine		P	Kemadrin Requip	DR	P	metaproterenol (oral) terbutaline	
inza		NP	Effexor XR		P	Requip Stalevo	DΚ	P	Maxair	
inza Jana ER		NP NP	nefazodone		NP	Azilect		P NP	Maxair Proventil HFA SCN	
sana ER sycontin		NP	Cymbalta		NP	Comtan		NP NP	Serevent Sch	
ram ER		NP	Emsam	SCN	NP	Mirapex	DR	NP	Ventolin HFA	
algesics, Narcotics	-Short-Actina		Wellbutrin XL*	0011	NP	Neupro	DIC	NP	Xopenex HFA	
ap/codeine, asp/cod		Р	* Prior authorization is not r	equired for rec		Parcopa		NP	metaproterenol (inhalation)	i
talbital/apap/codein		Р	18 and younger.	,	,	Tasmar		NP	Alupent	i
deine		P	Antidepressants, SSRI			Zelapar		NP	Brovana	i
yrocodeine/apap/ca	aff	Р	citalopram		Р	Antipsychotics, Atypica	al		Foradil	
dromorphone		P	fluoxetine		Р	clozapine		Р	ProAir HFA	1
drocodone/apap/ibu	ıp	P	fluvoxamine		Р	Geodon		Р	Xopenex	
profen/oxycodone		Р	paroxetine		P	Risperdal		P	Calcium Channel Blocking Agen	
orphanol		Р	sertraline		Р	Seroquel		P	amlodipine	
rphine		P	Lexapro		NP	Abilify		NP	diltiazem, ER	
rcodone/apap/asa		P	Paxil CR		NP	Fazaclo	SCN	NP	felodipine ER	
poxyphene HCL,ap	ар	P	Pexeva		NP	Invega		NP	nicardipine	1
madol		Р	Prozac Weekly		NP	Seroquel XR		NP	nifedipine, ER	1
tanyl buccal.		NP	Antiemetics, Oral			Symbyax		NP	nimodipine	
peridine		NP	ondansetron, oral, solution	on	Р	Zyprexa		NP	verapamil, ER, SR	
ntazocine/apap, nalo	xone	NP	Emend		P	Antivirals, Influenza			Cardizem LA	
madol/apap		NP	Anzemet		NP	amantadine		Р	Cardene SR	
ey:										
l lowercase letter	s = generic p	roduct		P = Prefe	rred :	product			QL = Quantity Limits	
ading capital letter			luct		•		o DA)		DR = Diagnosis Restriction	
aamg capitai iell					•	erred product (requires	,			
			DIC drugs and also for Le	wala 7h and 7	dana.	nat agreer drives that do n	bi		rl 'ara rahata agraamant	
N = Wisconsin Sen			viders should reference the						ē	Page 1

alcium Channel Blockir	ng (cont.)		Hepatitis C Agents			Macrolides/Ketolides			Ophthalmics, Glaucoma	Agents (con't.)	
ular		Р	ribavirin	DR	Р	azithromycin		Р	Lumigan			Р
radipine (Dynacirc, CR)		NP NP	Pegasys Peg-Intron, Redipen	DR DR SCN	P	clarithromycin		P P	Travatan, Z Trusopt			P P
ardene SR overa-HS		NP	Infergen	DR SCN		erythromycin Biaxin XL		P NP	Xalatan			P
ephalosporin and Relat	ed Agents		Hypoglycemics, Adjunc				CN	NP	Combigan			NF
moxicillin/clavulanate		P	Byetta [†]		P	Zmax		NP	Ophthalmics, NSAIDs			
nox tr-potassium clav (efaclor	600	P P	Janumet [†]	QL QL	P P	Multiple Sclerosis Agents Avonex	R SCN	D	diclofenac			P P
efadroxil		P	Januvia [†] Symlin [†] , pen [†]	QL	P	Betaseron D		P	flurbiprofen Acular, LS, PF			P
efdinir		P	† Preferred agents that re	quire clinical pric	or	Copaxone D	R SCN	Р	Nevanac			Р
efpodoxime		P	authorization.			Rebif D	R	Р	Xibrom			Р
ephalexin		P P	QL - Quantity Limits apply tablets Januvia, 68 tablets		4	NSAIDs		P	Otics, Fluoroquinolones ofloxacin (drops)			P
efprozil efuroxime		P	Hypoglycemics, Insuling			diclofenac, potassium, XL flurbiprofen		P	Ciprodex			P
edax		P	Humulin		Р	ibuprofen		Р	Floxin (singles)			Р
pectracef		P	Humalog		P	indomethacin, SR		P	Cipro HC			N
u prax ugmentin XR		P NP	Humalog Mix Lantus	SCN	P P	ketoprofen ketorolac		P P	Phosphate Binders Phoslo	SCN		P
orabid		NP	Levemir	3014	P	meclofenamate		P	Renagel	JUN		P
anixine		NP	Apidra	SCN	NP	meloxicam		P	Fosrenol			P
aniclor		NP				nabumetone		P	Platelet Aggregation Inhil	oitors		
ytokine and CAM Antag	onists SCN	P	Novolin Novolog		NP NP	naproxen		P P	dipyridamole			P P
nbrel [†] umira [†]	SUN	P	Novolog Novolog Mix		NP NP	naproxen sodium, DS piroxicam		P P	ticlopidine Aggrenox			P
umira [.] ineret [†]		P	*Exubera requires clinical	prior authorizati		Celebrex*		Р	Plavix			Р
aptiva [†]	SCN	Р	Hypoglycemics, Meglitin	nides		etodolac, XL		NP				
			Starlix		P	fenoprofen (Nalfon)		NP	Proton Pump Inhibitors	D.C.		P
			Prandin Hypoglycemics, Thiazol	lidinediones	NP	mefenamic acid (Ponstel) oxaprozin		NP NP	Nexium Prevacid (caps, SoluTab,	DR ei DR		P
Preferred agents that reg	uire clinical p	rior	Actos	namearones	Р	sulindac		NP	omeprazole*	DR		N
thorization.			Avandamet		Р	tolmetin, DS		NP	Aciphex*	DR		Ν
rythropoiesis Stimulatii			Avandaryl		P	Arthrotec		NP	Prilosec 40 mg*	DR		N
ranesp ·ocrit	DR DR	P P	Avandia		P NP	Prevacid Naprapac *Celebrex requires clinical prior	outhorizat	NP	Protonix* Zegerid*	DR DR		N
ogen	DR	NP	Actoplus MET Duetact		NP	Ophthalmics, Allergic Conjur		1011	* Requires the prior use an		of Nex	
uoroquinolones			Intranasal Rhinitis Agen	nts		Alaway		Р	and Prevacid.			
profloxacin		Р	flunisolide		Р	cromolyn		P	Sedative Hypnotics			
floxacin	CON	P P	ipratropium		P P	Zaditor OTC		P	chloral hydrate			P P
velox evaquin	SCN	P	Astelin fluticasone		P	ketotifen Alamast		NP NP	estazolam flurazepam			P
profloxacin ER		NP	Nasacort AQ	SCN	P	Alocril		NP	temazepam			P
pro suspension		NP	Beconase AQ		NP	Alomide		NP	triazolam			Ρ
active	SCN	NP	Nasarel		NP	Alrex		NP	zolpidem			P
axaquin oroxin		NP NP	Nasonex Rhinocort Aqua	SCN	NP NP	Elestat Emadine		NP NP	Rozerem Ambien CR	SCN		P N
roquin XR	SCN	NP	Veramyst		NP	Patanol		NP	Doral	0014		N
equin		NP	Leukotriene Modifiers			Pataday		NP	Lunesta			N
lucocorticoids, Inhaled			Accolate		P	Optivar		NP	Restoril			N
dvair, HFA erobid. Aerobid-M	SCN	P P	Singulair Zyflo		P NP	Ophthalmics, Fluoroquinolor	ies	P	Sonata Stimulants and Related A	aonto		N
smanex	SCN	P	Lipotropics, Bile Acid S	equestrants	INF	bacitracin/polymyxin ciprofloxacin solution		P	amphetamine salt combo	_		Р
zmacort	SCN	P	cholestyramine	•	Р	erythromycin		Р	dextroamphetamine	DR		Р
ovent, HFA		Р	colestipol		Р	gentamicin		P	methylphenidate, ER	DR		Ρ
ulmicort Respules		P	Welchol		NP	ofloxacin		P	Adderall XR	DR		Р
var ulmicort Flexhaler		P NP	Lipotropics, Fibric Acide fenofibrate	S	P	polymyxin/trimethoprim sulfacetamide		P P	Concerta Focalin, XR	DR DR		P P
ymbicort		NP	gemfibrozil		Р	tobramycin		Р	Metadate CD	DR		Р
rowth Hormone			Tricor		Р	triple antibiotic		Р	pemoline (Cylert)	DR		Ν
enotropin [†]	0011	P	Antara		NP	Vigamox		P	Daytrana	DR	001	N
utropin AQ [†] aizen [†]	SCN	P P	Triglide Lipotropics, Other		NP	Zymar Ciloxan Ointment		P NP	Desoxyn Provigil	DR DR	SCN	N N
aizen [.] ev-Tropin [†]		Р	Niaspan		Р	Iquix		NP	Ritalin LA	DR		N
umatrope		NP	Lovaza (Omacor)		NP	Quixin		NP	Strattera*	DR		N
orditropin		NP	Zetia		NP	Ophthalmics, Glaucoma Age	nts		Vyvanse	DR		N
utropin mnitrope	SCN	NP NP	Lipotropics, Statins lovastatin		Р	betaxolol brimonidine		P P	* Prior authorization is not r 18 and older.	equired 1	for reci	ipie
erostim		NP	simvastatin		P	carteolol		P	Topical Immunomodulato	rs		
orbtive		NP	Advicor		Р	dipivefrin		Р	Elidel			N
Preferred agents that req	uire clinical p	rior	Lescol, XL		P	levobunolol		P	Protopic	SCN		N
thorization.			Lipitor		P	metipranolol		P	Ulcerative Colitis			Ę
epatitis B Agents araclude		Р	Vytorin pravastatin		P NP	pilocarpine timolol		P P	mesalamine sulfasalazine			P
oivir HBV		P	Altoprev		NP	Alphagan P		P	Asacol			P
epsera		P	Caduet		NP	Azopt		P	Canasa			P
/zeka		Р	Crestor		NP	Betimol		P	Colazal	SCN		P
						Betopic S Cosopt		P P	Dipentum Lialda			N
						Istalol		P	Pentasa			N
ey:						, - 						
ll lowercase letters =	= generic n	roduct		P = Prefe	rrad	nroduct			QL = Quantity Limits			
	peneric p	Jauet		1 - 11616	u	product			~ ~ vamury Limits			

dhfs.wisconsin.gov/seniorcare or via hand held devices using ePocrates (www.ePocrates.com)

ATTACHMENT 2 BadgerCare Plus-Covered Drug-Related Supplies

(A list of the BadgerCare Plus-Covered Drug-Related Supplies is located on the following pages.)

The following is a list of procedure codes, modifiers, and descriptions for BadgerCare Plus-covered drug-related supplies.

Procedure Code	Modifier	Description	
A4206		Syringe with needle; sterile 1cc, each	
A4207		sterile 2cc, each	
A4208		sterile 3cc, each	
A4209		sterile 5cc or greater, each	
A4213		Syringe, sterile, 20cc or greater, each	
A4215		Needle, sterile, any size, each	
A4215	22	Insulin pen needles	
A4215	59	Huber needles	
A4233		Replacement battery, alkaline (other than J cell), for use with medically necessary home blood glucose monitor owned by patient, each	
A4234		Replacement battery, alkaline, J cell, for use with medically necessary home blood glucose monitor owned by patient, each	
A4235		Replacement battery, Lithium, for use with medically necessary home blood glucose monitor owned by patient, each	
A4236		Replacement battery, silver oxide, for use with medically necessary home blood glucose monitor owned by patient, each	
A4244		Alcohol or peroxide, per pint	
A4250		Urine test or reagent strips or tablets (100 tablets or strips)	
A4253	KS	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips, TYPE Il Diabetics	
A4253	KX	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips, TYPE I Diabetics	
A4256		Normal, low and high calibrator solution/chips	
A4258		Spring Powered Device for lancet, each	
A4258	22	Insulin pen	
A4259	KS	Lancets, per box of 100, Type II Diabetics	
A4259	KX	Lancets, per box of 100, Type I Diabetics	
A4261		Cervical cap for contraceptive use	
A4266		Diaphragm for contraceptive use	
A4267		Contraceptive supply, condom, male, each	
A4268		Contraceptive supply, condom, female, each	
A4269		Contraceptive supply, spermacide (e.g., foam, gel), each	
A4614		Peak expiratory flow rate meter, hand held	
A4627		Spacer, bag or reservoir, with or without mask, for use with metered dose inhaler	
A7003		Administration set, with small volume non-filtered pneumatic nebulizer, disposable	

Procedure	Modifier	Description					
Code	Modifier						
A7004		Small volume nonfiltered pneumatic nebulizer, disposable					
A7005		Administration set, with small volume nonfiltered pneumatic nebulizer, non-disposable					
A7006		Administration set, with small volume filtered pneumatic nebulizer					
A7015		Aerosol mask, used with DME nebulizer					
A7016		Dome and mouthpiece, used with small volume ultrasonic nebulizer					
A7018		Water, distilled, used with large volume nebulizer, 1000 ml					
A7018	22	Sterile water irrigation solution, 1000 ml					
A7018	59	Sterile saline irrigation solution, 1000 ml					
E0570		Nebulizer; With Compressor e.g., Devilbiss Pulmo-Aid					
E0570	RR	Nebulizer; With Compressor e.g., Devilbiss Pulmo-Aid					
E0571		Aerosol Compressor, Battery Powered, For Use With Small Volume Nebulizer					
E0571	RR	Aerosol Compressor, Battery Powered, For Use With Small Volume Nebulizer					
E0575		Nebulizer, Ultrasonic, Large Volume					
E0575	RR	Nebulizer, Ultrasonic, Large Volume					
F0.500		Nebulizer, With Compressor, Durable, Glass Or Autoclavable Plastic, Bottle Type, For					
E0580		Use With Regulator Or Flowmeter					
E0585		Nebulizer; With Compressor And Heater					
E0585	RR	Nebulizer; With Compressor And Heater					
E0607		Home blood glucose monitor					
E1372		Immersion External Heater For Nebulizer					
E1372	RR	Immersion External Heater For Nebulizer					
E2100		Blood glucose monitor with integrated voice synthesizer					
E2101		Blood glucose monitor with integrated lancing/blood sample					
\$5000	U1-U5	Prescription drug, generic					
\$5001	U1-U5	Prescription drug, brand name					
S8101		Holding chamber or spacer for use with an inhaler or nebulizer; with mask					
S8490		Insulin syringes (100 syringes, any size)					